Bicara Therapeutics Inc. BCAX
19.21
(0.57)
(2.88%)
as of 25 Sep
- Market cap
- $1.3B
- P/E
- 0.0×
Follow BCAX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (41.01%) | (32.34%) | (30.88%) | (26.64%) |
+7 more TTM periods Free account |
|
| (38.38%) | (30.50%) | (29.32%) | (25.61%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (78.32%) | |
Return on Tangible Assets |
(40.23%) | (31.09%) | (35.06%) | (43.95%) | |
Free Cash Flow per Share |
(1.99) | (1.92) | (1.96) | (2.07) | |
Free Cash Flow |
(135.25) | (116.62) | (107.16) | (113.09) | |
Capital Expenditures |
(0.40) | (0.38) | (0.33) | (0.11) | |
Piotroski F-Score |
2.00 | 2.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(13.96%) | (11.03%) | (13.09%) | (16.30%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.74 | 0.77 | 0.93 | |
Depreciation/Fixed assets |
2.85 | 2.22 | 1.23 | 0.81 | |
Capex/Depreciation |
(0.39) | (0.49) | (0.81) | (1.00) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.99) | (1.91) | (1.95) | (2.07) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates